

<b>CONTENTS</b>	<b>PAGE NO.</b>
<b>CHAPTER 1: INTRODUCTION</b>	<b>1-36</b>
1.1. Analytical Methods	2
1.1.1. Stability Indicating Assay Method (SIAMs)	2
1.1.2. Development of HPLC method	14
1.1.3. Development of HPTLC method	23
1.1.4. Validation of analytical methods	25
1.1.5. Quality by Design (QbD) and Design of Experiments (DoE)	27
1.2. References	32
<b>CHAPTER 2 : AIMS AND OBJECTIVES</b>	<b>37-38</b>
<b>CHAPTER 3: DEVELOPMENT OF STABILITY INDICATING METHOD OF CLEVIDIPINE BUTYRATE</b>	<b>39-81</b>
3.1. SELECTION OF DRUG	39
3.2. DRUG PROFILE	39
3.3. LITERATURE REVIEW	41
<b>3.4. SECTION - A</b>	<b>43-62</b>
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD	
3.4.1. EXPERIMENTAL	43
3.4.2. RESULTS	
3.4.2.1. Determination of suitable wavelength	46
3.4.2.2. Method optimization and development	47
3.4.2.3. Method Validation using ICH Q2(R1) guideline	49
3.4.2.4. Stress Degradation studies	54
3.4.2.5. Applicability of developed stability indicating assay method for analysis of formulation (Synthetic mixture)	59
3.4.3. DISCUSSIONS	60

<b>3.5. SECTION - B</b>	
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPTLC METHOD	<b>63-79</b>
3.5.1. EXPERIMENTAL	63
3.5.2. RESULTS	
3.5.2.1. Determination of suitable wavelength	66
3.5.2.2. Method optimization and development	66
3.5.2.3. Method Validation using ICH Q2(R1) guideline	68
3.5.2.4. Stress Degradation studies	72
3.5.2.5. Applicability of developed stability indicating assay method for analysis of formulation (Synthetic mixture)	76
3.5.2.6. Comparison of HPLC and HPTLC methods for Clevidipine	77
3.5.3. DISCUSSIONS	79
3.6. CONCLUSION	79
3.7. REFERENCES	80
<b>CHAPTER 4: DEVELOPMENT OF STABILITY INDICATING METHOD OF ACOTIAMIDE HCL TRIHYDRATE</b>	<b>82-141</b>
4.1. SELECTION OF DRUG	82
4.2. DRUG PROFILE	82
4.3. LITERATURE REVIEW	83
<b>4.4. SECTION- A</b>	
DEVELOPMENT OF STABILITY INDICATING METHOD	<b>86-105</b>
4.4.1. EXPERIMENTAL	86
4.4.2. RESULTS	
4.4.2.1. Determination of suitable wavelength	90
4.4.2.2. Method optimization and development	90
4.4.2.3. Method Validation using ICH Q2(R1) guideline	93
4.4.2.4. Stress Degradation studies	98
4.4.2.5. Applicability of developed stability indicating assay method for analysis of formulation	104
4.4.3. DISCUSSIONS	104

<b>4.5. SECTION - B</b>	
ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF ACOTIAMIDE HCL TRIHYDRATE	<b>106-130</b>
4.5.1. EXPERIMENTAL	106
4.5.2. RESULTS AND DISCUSSION	
4.5.2.1. Identification of degradation products	109
<b>4.6. SECTION - C</b>	
IMPURITY PROFILING AND DEGRADATION STUDY OF ACOTIAMIDE HCL TRIHYDRATE	<b>131-138</b>
4.6.1. EXPERIMENTAL	131
4.6.2. RESULTS AND DISCUSSION	
4.6.2.1. LC-PDA Study	131
4.6.2.2. LC-MS study and characterization of DPs	132
4.6.2.3. Degradation pathway and mechanism of formation of DPs	134
4.7. CONCLUSION	139
4.8. REFERENCES	139
<b>CHAPTER 5: DEVELOPMENT OF STABILITY INDICATING METHOD OF FIMASARTAN POTASSIUM</b>	<b>142-203</b>
5.1. SELECTION OF DRUG	142
5.2.DRUG PROFILE	142
5.3.LITERATURE REVIEW	143
<b>5.4.SECTION - A</b>	
DEVELOPMENT OF STABILITY INDICATING METHOD	<b>146-164</b>
5.4.1. EXPERIMENTAL	146
5.4.2. RESULTS	
5.4.2.1. Determination of suitable wavelength	150
5.4.2.2. Method optimization and development	150
5.4.2.3. Method Validation using ICH Q2(R1) guideline	152
5.4.2.4. Stress Degradation studies	158
5.4.2.5. Applicability of developed stability indicating assay method for analysis of formulation (synthetic mixture)	164
5.4.3. DISCUSSIONS	164

<b>5.5. SECTION - B</b> DEGRADATION KINETICS STUDY OF FIMASARTAN POTASSIUM BY HPLC METHOD	<b>165-169</b>
5.5.1. EXPERIMENTAL	165
5.5.2. RESULTS (kinetics of oxidative degradation)	165
5.5.3. DISCUSSIONS	169
<b>5.6. SECTION - C</b> ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCT OF FIMASARTAN POTASSIUM	<b>170-191</b>
5.6.1. EXPERIMENTAL	170
5.6.2. RESULTS	172
5.6.3. DISCUSSIONS	191
<b>5.7. SECTION - D</b> IMPURITY PROFILING AND DEGRADATION STUDY OF FIMASARTAN POTASSIUM	<b>192-200</b>
5.7.1. EXPERIMENTAL	192
5.7.2. RESULTS	
5.7.2.1. LC-PDA Study	192
5.7.2.2. LC-MS study and characterization of DPs	193
5.7.2.3. Degradation pathway of FIMASARTAN POTASSIUM	197
5.7.3. DISCUSSIONS	200
5.8. CONCLUSION	200
5.9. REFERENCES	201
<b>CHAPTER 6: DEVELOPMENT OF STABILITY INDICATING METHOD OF ANAGLIPTIN</b>	<b>204-283</b>
6.1. SELECTION OF DRUG	204
6.2. DRUG PROFILE	204
6.3. LITERATURE REVIEW	205
<b>6.4. SECTION –A</b> DEVELOPMENT OF STABILITY INDICATING METHOD	<b>207-229</b>
6.4.1 EXPERIMENTAL	207
6.4.2 RESULTS	
6.4.2.1 Determination of suitable wavelength	211

6.4.2.2 Method optimization and development	212
6.4.2.3 Method Validation using ICH Q2(R1) guideline	214
6.4.2.4 Stress Degradation studies	219
6.4.2.5 Applicability of developed stability indicating assay method for analysis formulation (synthetic mixture)	228
6.4.3. DISCUSSIONS	229
<b>6.5. SECTION-B</b> DEGRADATION KINETIC STUDY OF ANAGLIPTIN BY HPLCMETHOD	<b>230-238</b>
6.5.1. EXPERIMENTAL	230
6.5.2. RESULTS	
6.5.2.1. Alkaline degradation kinetics study	231
6.5.2.2. Oxidative degradation kinetics study	235
6.5.3. DISCUSSIONS	238
<b>6.6. SECTION –C</b> ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF ANAGLIPTIN	<b>239-270</b>
6.6.1. EXPERIMENTAL	239
6.6.2. RESULTS	
6.6.2.1. Structural characterization of Anagliptin and degradation products	242
6.6.3. DISCUSSIONS	270
<b>6.7. SECTION-D</b> IMPURITY PROFILING AND DEGRADATION STUDY OF ANAGLIPTIN	<b>271-281</b>
6.7.1. EXPERIMENTAL	271
6.7.2. RESULTS	
6.7.2.1. LC-PDA Study	271
6.7.2.2. LC-MS study and characterization of DPs	273
6.7.2.3. Degradation pathway of ANAGLIPTIN	277
6.7.3. DISCUSSIONS	280

6.8.CONCLUSION	282
6.9. REFERENCES	282
<b>CHAPTER 7: DEVELOPMENT OF STABILITY INDICATING METHOD OF EFONIDIPINE HCL ETHANOLATE</b>	<b>284-387</b>
7.1. SELECTION OF DRUG	284
7.2.DRUG PROFILE	285
7.3.LITERATURE REVIEW	285
<b>7.4.SECTION - A</b> METHOD DEVELOPMENT OF EFONIDIPINE HCL ETHANOLATE BY QBD	<b>286-307</b>
7.4.1. EXPERIMENTAL	286
7.4.2. RESULTS	295
7.4.3. DISCUSSIONS	304
<b>7.5. SECTION - B</b> DEVELOPMENT OF STABILITY INDICATING METHOD OF EFONIDIPINE HCL ETHANOLATE	<b>306-323</b>
7.5.1. EXPERIMENTAL	306
7.5.2. RESULTS	
7.5.2.1.Method optimization and development	309
7.5.2.2.Method Validation using ICH Q2(R1) guideline	311
7.5.2.3. Stress Degradation studies	317
7.5.2.4. Applicability of developed stability indicating assay method for analysis of formulation	323
7.6. DISCUSSIONS	323
<b>7.6. SECTION- C</b> DEGRADATION KINETICS STUDY OF EFONIDIPINE HCL ETHANOLATE BY HPLC METHOD	<b>324-329</b>
7.6.1. EXPERIMENTAL	324
7.6.2. RESULTS (kinetics of alkaline degradation)	324
7.6.3. DISCUSSIONS	329

<b>7.7. SECTION - D</b>	
ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF EFONIDIPINE HCL ETHANOLATE	<b>330-367</b>
7.7.1. EXPERIMENTAL	330
7.7.2. RESULTS AND DISCUSSION	
7.7.2.1. Structural characterization of Efonidipine and degradation products	332
<b>7.8. SECTION - E</b>	
IMPURITY PROFILING AND DEGRADATION STUDY OF EFONIDIPINE HCL ETHANOLATE	<b>368-387</b>
7.8.1. EXPERIMENTAL	368
7.8.2. RESULTS AND DISCUSSION	
7.8.2.1. LC-PDA Study	368
7.8.2.2. LC-MS study and characterization of DPs	370
7.8.2.3. Degradation pathway of EFONIDIPINE HCL ETHANOLATE	378
7.9. CONCLUSION	385
7.10. REFERENCES	385
<b>CHAPTER 8: DEVELOPMENT OF STABILITY INDICATING METHOD OF RIOCIQUAT</b>	<b>388 -461</b>
8.1. SELECTION OF DRUG	388
8.2. DRUG PROFILE	388
8.3. LITERATURE REVIEW	389
<b>8.4. SECTION - A</b>	
STABILITY INDICATING METHOD DEVELOPMENT	<b>390-412</b>
8.4.1. EXPERIMENTAL	390
8.4.2. RESULTS	
8.4.2.1. Determination of suitable wavelength	394
8.4.2.2. Method optimization and development	394
8.4.2.3. Method Validation using ICH Q2(R1) guideline	396
8.4.2.4. Stress Degradation studies	406
8.4.2.5. Applicability of developed stability indicating assay method for analysis formulation (synthetic mixture)	412

8.4.3. DISCUSSIONS	412
<b>8.5. SECTION - B</b> DEGRADATION KINETICS STUDY OF RIOCIQUAT BY HPLC METHOD	<b>413- 418</b>
8.5.1. EXPERIMENTAL	413
8.5.2. RESULTS (kinetics of alkaline degradation)	413
8.5.3. DISCUSSIONS	418
<b>8.6. SECTION - C</b> ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF RIOCIQUAT	<b>419-454</b>
8.6.1. EXPERIMENTAL	419
8.6.2. RESULTS	
8.6.2.1. Structural characterization of Riociguat and degradation products	421
8.6.3. DISCUSSIONS	453
<b>8.7. SECTION - D</b> IMPURITY PROFILING AND DEGRADATION STUDY OF RIOCIQUAT	<b>455 -461</b>
8.7.1. EXPERIMENTAL	455
8.7.2. RESULTS	
8.7.2.1. LC-PDA Study	455
8.7.2.2. LC-MS study and characterization of DPs	456
8.7.2.3. Degradation pathway of RIOCIQUAT	457
8.7.3. DISCUSSIONS	459
8.8. CONCLUSION	460
8.9. REFERENCES	460
<b>CHAPTER 9: SUMMARY</b>	<b>462-471</b>
<b>LIST OF PUBLICATIONS AND PRESENTATIONS</b>	<b>472-473</b>